Diversified Trust Co boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 19.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,573 shares of the life sciences company’s stock after acquiring an additional 1,060 shares during the quarter. Diversified Trust Co’s holdings in Illumina were worth $2,000,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of ILMN. Nuveen Asset Management LLC raised its holdings in shares of Illumina by 67,829.8% in the second quarter. Nuveen Asset Management LLC now owns 2,260,705 shares of the life sciences company’s stock valued at $832,279,000 after purchasing an additional 2,257,377 shares during the last quarter. Thoroughbred Financial Services LLC lifted its holdings in shares of Illumina by 38,516.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock worth $87,583,000 after purchasing an additional 873,560 shares in the last quarter. Baillie Gifford & Co. raised its position in Illumina by 5.0% in the 2nd quarter. Baillie Gifford & Co. now owns 16,775,175 shares of the life sciences company’s stock valued at $6,175,781,000 after buying an additional 799,884 shares during the last quarter. American Century Companies Inc. increased its position in shares of Illumina by 107.1% during the 1st quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock valued at $253,484,000 after purchasing an additional 421,953 shares during the last quarter. Finally, Jennison Associates LLC increased its holdings in Illumina by 5.2% in the 2nd quarter. Jennison Associates LLC now owns 5,976,219 shares of the life sciences company’s stock worth $2,200,145,000 after acquiring an additional 296,541 shares during the last quarter. 90.90% of the stock is currently owned by institutional investors.
In other Illumina news, SVP Charles Dadswell sold 124 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $300.00, for a total value of $37,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Oene Mark Van sold 625 shares of the stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $304.84, for a total transaction of $190,525.00. Following the completion of the transaction, the senior vice president now directly owns 14,209 shares of the company’s stock, valued at $4,331,471.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,099 shares of company stock valued at $13,897,460. 0.38% of the stock is owned by insiders.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The firm had revenue of $838.00 million for the quarter, compared to the consensus estimate of $835.12 million. During the same period in the prior year, the company posted $1.43 earnings per share. The company’s quarterly revenue was up 1.0% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 6.04 EPS for the current year.
A number of equities analysts recently weighed in on the company. UBS Group raised their price objective on Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Friday, September 13th. Deutsche Bank reduced their target price on Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a research note on Friday, July 12th. Piper Jaffray Companies set a $348.00 price target on Illumina and gave the company a “buy” rating in a research report on Friday, September 27th. Finally, ValuEngine upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company. Illumina has a consensus rating of “Buy” and a consensus target price of $330.92.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.